Who We Are: Clinical-Stage T1D Biopharma

Overview

Who we are

Woman helping a young girl check her blood sugar while sitting together on couch

SAB BIO is a clinical-stage biopharmaceutical company developing multispecific human immunoglobulin G therapies (hIgG) to treat and prevent type 1 diabetes (T1D) and other autoimmune disorders.

Founded in 2014, we use advanced genetic engineering and proprietary antibody technology to develop novel therapeutics. Our lead candidate, SAB-142, is a potential disease-modifying treatment for autoimmune T1D, designed to delay onset and potentially prevent disease progression. SAB-142 is being evaluated in clinical trials across the T1D disease continuum, including the SAFEGUARD study for those newly diagnosed in Stage 3 T1D and the investigator-led PRISE-hATG study for people up to 2 years from a Stage 3 T1D diagnosis.

Meet our leadership team

Smiling man talking on his phone at home, wearing a sensor patch on his upper arm

The vision, mission, and values behind our pursuit of disease modification

Our vision is clear: To transform outcomes for people with autoimmune disease through disease modification.

At SAB BIO, our mission is to dramatically redefine what it means to be diagnosed with T1D by developing a medicine to change the course of disease, not just treat symptoms. It is what drives the work we do.

Four values guide how we do that work

Put people first

We see the person and the families behind every diagnosis.

Rethink what’s possible

We are brave enough to see the potential and bold enough to explore what’s possible.

Move with urgency

We move fast because every day counts.

Deliver excellence

We say it, we mean it, we prove it.

Discover our pipeline

Learn how SAB-142 works

PRISE-hATG=Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Extended New Onset T1D Treated with human Anti-Thymocyte Globulin.
SAFEGUARD=SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes.